The text provides condensed financial information for AbbVie Inc., including their statements of earnings, comprehensive income, and balance sheets for the three and nine months ended September 30 in 2021 and 2020. The data includes net revenues, operating expenses, earnings per share, assets, liabilities, and equity, offering insight into the company's financial performance and position during these periods. AbbVie has collaboration agreements with Janssen for Imbruvica and Genentech for Venclexta. These partnerships involve milestone payments, cost sharing for development expenses, profit and loss sharing, royalty payments for international sales, and discussions about financial components like goodwill, intangible assets, integration plans post Allergan acquisition, and the company's utilization of financial instruments like derivatives for risk management purposes.
The text provided gives an overview of the financial condition and results of operations for AbbVie Inc. The company's acquisition of Allergan expanded its product portfolio in various therapeutic areas. AbbVie reported significant revenue growth in 2021, driven by key products like Humira, Skyrizi, Rinvoq, Venclexta, and Botox, both in the US and internationally. The financial performance included increased net revenues, operating earnings, diluted earnings per share, and cash flows. The company outlined strategic objectives for 2021, involving maximizing benefits from the Allergan acquisition, advancing its pipeline, expanding operating margins, and returning cash to shareholders. Additionally, the text covers financial metrics like gross margin, SG&A expenses, R&D expenses, investment activities, and further discusses credit risk, access to capital, and critical accounting policies. Lastly, it concludes with forward-looking statements and risk factors affecting AbbVie's operations.
Refer to AbbVie's Annual Report on Form 10-K for the year that ended on December 31, 2020 for a detailed discussion on the company's market risk under "Quantitative and Qualitative Disclosures About Market Risk" in Item 7A.
The text discusses the evaluation of AbbVie's disclosure controls and procedures by the Chief Executive Officer and Chief Financial Officer, confirming their effectiveness in ensuring timely and accurate disclosure of required information to the Securities and Exchange Commission. Additionally, it mentions that there were no changes in AbbVie's internal control over financial reporting during the period covered, with recognition that no control system can prevent or detect all errors and fraud due to inherent limitations and resource constraints. Management also states that controls may become inadequate over time due to changes in conditions or compliance levels with policies and procedures.
The text provided refers to legal proceedings information included in Note 12 of the Condensed Consolidated Financial Statements, which is referenced in the document.
I'm ready for the text parts. Please go ahead and share them with me.
The text provided discusses the unregistered sales of equity securities and the issuer purchases of equity securities for AbbVie within specific periods from July to September 2021. During this time, a total of 2,846 shares were purchased at an average price of $112.74 per share, with a total dollar amount of $2,643,316,927. These shares were part of publicly announced plans or programs and included shares purchased for the AbbVie Employee Stock Purchase Plan participants. The information does not include shares surrendered for tax purposes related to stock-based awards.
I am sorry, I cannot provide a summary as you have not provided any text for me to summarize. Please send me the text that needs to be summarized.
I am ready to receive the text in parts whenever you are ready to send them.
I am ready to summarize the text whenever you are ready.
The text provides detailed information about various exhibits accompanying AbbVie Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. These exhibits include certifications by the Chief Executive Officer and Chief Financial Officer as required by regulations. Additionally, there are financial statements and notes formatted in iXBRL, the Cover Page Interactive Data File, and a signature by the Chief Financial Officer confirming the report's authenticity.
